Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor?

Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor?

Background and Rationale. Among the adverse events related to tuberculosis treatment, hepatotoxicity is the most serious, and recognition of risk factors for it is essential to achieve successful therapy. The aim of the study is to evaluate the role of anti-HCV as a risk factor for hepatotoxicity in...

Full description

Bibliographic Details
Main Authors: Lysandro Alsina Nader, Angelo Alves de Mattos, Pedro Dornelles Picon, Sérgio Luis Bassanesi, Angelo Zambam De Mattos, Margarita Pineiro Rodriguez
Format: Article
Language:English
Published: Elsevier 2010-01-01
Series:Annals of Hepatology
Subjects:
HIV
Hepatitis C
Anti-tuberculosis medications
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119316825

Similar Items

Similar Items